BioVie Inc. announced on September 25, 2024, the closing of its previously announced best efforts public offering. The offering included 1,360,800 shares of common stock, pre-funded warrants for 600,000 shares, and common warrants to purchase up to 1,960,800 shares.
The securities were offered at a combined public offering price of $1.53 per share (or pre-funded warrant) and associated common warrant. The common warrants have an exercise price of $1.53 per share and are immediately exercisable for five years.
The gross proceeds to BioVie from this offering totaled approximately $3,000,000, before deducting placement agent fees and offering expenses. The company plans to use the net proceeds for working capital and general corporate purposes.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.